Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melhem Solh

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|August 18, 2012
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)Melhem Solh, Kanti R Rai, Bercedis L Peterson, et al.
The AAPS Journal|December 11, 2021
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin LymphomaBrian Hess, William Townsend, Weiyun Ai, et al.
Blood Advances|June 28, 2023
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplantScott R Solomon, Melhem Solh, Lawrence E Morris, et al.
Bone Marrow Transplantation|July 31, 2024
HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantationMelhem Solh, Michael T Aubrey, Xu Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2019
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBrad S Kahl, Mehdi Hamadani, John Radford, et al.
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Haematologica|September 5, 2024
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapySantiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Haematologica|May 19, 2019
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|August 18, 2012
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)Melhem Solh, Kanti R Rai, Bercedis L Peterson, et al.
The AAPS Journal|December 11, 2021
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin LymphomaBrian Hess, William Townsend, Weiyun Ai, et al.
Blood Advances|June 28, 2023
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplantScott R Solomon, Melhem Solh, Lawrence E Morris, et al.
Bone Marrow Transplantation|July 31, 2024
HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantationMelhem Solh, Michael T Aubrey, Xu Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2019
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBrad S Kahl, Mehdi Hamadani, John Radford, et al.
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Haematologica|September 5, 2024
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapySantiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Haematologica|May 19, 2019
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, et al.
Pageof 11